Substrate specificity of human cathepsin D using internally quenched fluorescent peptides derived from reactive site loop of kallistatin.

Kallistatin, a serpin that specifically inhibits human tissue kallikrein, was demonstrated to be cleaved at the Phe-Phe bond in its reactive site loop (RSL) by cathepsin D. Internally quenched fluorescent peptides containing the amino acid sequence of kallistatin RSL were highly susceptible to hydrolysis by cathepsin D. Surprisingly, these peptides were efficiently hydrolyzed at Phe-Phe bond, despite having Lys and Ser at P2 and P2' positions, respectively, which was reported to be very unfavorable for substrates for cathepsin D. Due to the importance of cathepsin D in several physiological and pathological processes, we took the peptide containing kallistatin RSL sequence, Abz-Ala-Ile-Lys-Phe-Phe-Ser-Arg-Gln-EDDnp, as a reference substrate for a systematic specificity study of S3 to S3' protease subsites (EDDnp=N-[2,4-dinitrophenyl]-ethylenediamine and Abz=ortho-amino benzoic acid). We present in this paper some internally quenched fluorescent peptides that were efficient substrates for cathepsin D. They essentially differ from other previously described substrates by their higher kcat/Km values due, mainly, to low Km values, such as the substrate Abz-Ala-Ile-Ala-Phe-Phe-Ser-Arg-Gln-EDDnp (Km=0.27 microM, kcat=16.25 s(-1), kcat/Km=60185 microM(-1) x s(-1)).

[1]  C. G. Knight.  [6] Active-site titration of peptidases , 1995 .

[2]  L. Juliano,et al.  α1-Antichymotrypsin and Kallistatin Hydrolysis by Human Cathepsin D , 2000, Journal of protein chemistry.

[3]  A. Barrett,et al.  Inhibition of cysteine proteinases and dipeptidyl peptidase I by egg-white cystatin. , 1984, The Biochemical journal.

[4]  B. Dunn,et al.  A systematic series of synthetic chromophoric substrates for aspartic proteinases. , 1986, The Biochemical journal.

[5]  A. V. D. Drift,et al.  The selectivity of cathepsin D suggests an involvement of the enzyme in the generation of T-cell epitopes. , 1989 .

[6]  B. Dunn,et al.  Redesign of the substrate specificity of human cathepsin D: the dominant role of position 287 in the S2 subsite. , 1994, Protein engineering.

[7]  S. Diment,et al.  Role of cathepsin D in antigen presentation of ovalbumin. , 1992, Journal of immunology.

[8]  P. Cresswell,et al.  Co-localization of molecules involved in antigen processing and presentation in an early endocytic compartment , 1990, Nature.

[9]  J. Gierse,et al.  Substrate specificity of recombinant human renal renin: effect of histidine in the P2 subsite on pH dependence. , 1990, Biochemistry.

[10]  T L Blundell,et al.  Exploration of subsite binding specificity of human cathepsin D through kinetics and rule‐based molecular modeling , 1993, Protein science : a publication of the Protein Society.

[11]  L. Suvorov,et al.  Fluorogenic peptide substrates for assay of aspartyl proteinases. , 1996, Analytical biochemistry.

[12]  T. Saku,et al.  Quantitation and immunohistochemical localization of cathepsins E and D in rat tissues and blood cells. , 1989, Biochimica et biophysica acta.

[13]  H. Rammensee,et al.  Substrate specificity of cathepsins D and E determined by N-terminal and C-terminal sequencing of peptide pools. , 1997, European journal of biochemistry.

[14]  H. Rochefort,et al.  Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[15]  John W. Erickson,et al.  Conformational switching in an aspartic proteinase , 1998, Nature Structural Biology.

[16]  J. V. van Noort,et al.  Cathepsin D, but not cathepsin B, releases T cell stimulatory fragments from lysozyme that are functional in the context of multiple murine class II MHC molecules , 1994, European journal of immunology.

[17]  S. Gulnik,et al.  Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues. , 1997, Biochemistry.

[18]  L. Chao,et al.  Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. , 1993, The Journal of biological chemistry.

[19]  L. Juliano,et al.  Hydrolysis of somatostatin by human tissue kallikrein after the amino acid pair phe-Phe. , 1997, The Biochemical journal.

[20]  J. Collins,et al.  Design of sensitive fluorogenic substrates for human cathepsin D , 1997, FEBS letters.

[21]  J. Collins,et al.  Structure‐based subsite specificity mapping of human cathepsin D using statine‐based inhibitors , 1997, Protein science : a publication of the Protein Society.

[22]  Isleifur Olafsson,et al.  Inactivation of human cystatin C and kininogen by human cathepsin D , 1991, FEBS letters.

[23]  S. Diment.  Different roles for thiol and aspartyl proteases in antigen presentation of ovalbumin. , 1990, Journal of immunology.

[24]  J. Kay,et al.  Natural processing sites for human cathepsin E and cathepsin D in tetanus toxin: implications for T cell epitope generation. , 1997, Journal of immunology.

[25]  J. Hartsuck,et al.  pH dependence of kinetic parameters of pepsin, rhizopuspepsin, and their active-site hydrogen bond mutants. , 1992, The Journal of biological chemistry.

[26]  G. N. Wilkinson.  Statistical estimations in enzyme kinetics. , 1961, The Biochemical journal.

[27]  H. Rochefort,et al.  In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. , 1988, Cancer research.

[28]  Orekhovich Vn,et al.  Kininogenase activity of cathepsins D , 1980 .

[29]  L. Chao,et al.  Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. , 1992, The Journal of biological chemistry.

[30]  B. Dunn,et al.  Prime region subsite specificity characterization of human cathepsin D: The dominant role of position 128 , 1998, Protein science : a publication of the Protein Society.

[31]  J. Ni,et al.  Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.